Anidulafungin-Induced Alopecia
Autores de IIS La Fe
Grupos
Abstract
Objetive: To report a case of a woman in whom alopecia appeared after several months of treatment with anidulafungin. Case Summary: A 34-year-old woman with chronic femoral osteomyelitis with the presence of persistent suppuration, developed a Candida albicans infection, isolated in the fistula exudate cultures. After initial failures of single therapy with azoles, it was decided to administer fluconazole and anidulafungin 100 mg/d. One month after starting the treatment, the patient mentioned a greater hair loss than usual. At 3 months, the patient stopped taking the drug on noting the loss and easy falling out of her hair, with alopecia plaques 1 to 2 cm in size. At 2 months after stopping the anidulafungin, it was decided to restart combined antifungal treatment using micafungin and fluconazole; there was no mention of new or greater loss of hair. It was decided to change micafungin to anidulafungin again 90 days after starting treatment. In the first month of treatment, there appeared to be a reactivation in hair loss that later stabilized and improved. Discussion: Drug-induced hair loss is an adverse reaction that has been identified during different hair growth phases. It has been described for the azoles group and has not been associated with candins until now. Results of the causality analysis, using the probability scale established by Naranjo, found the relationship as probable. Conclusions: Anidulafungin could be associated with hair loss. Physicians
Datos de la publicación
- ISSN/ISSNe:
- 1060-0280, 1542-6270
- Tipo:
- Article
- Páginas:
- 660-662
- PubMed:
- 24604921
- Factor de Impacto:
- 0,819 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
ANNALS OF PHARMACOTHERAPY SAGE PUBLICATIONS INC
Citas Recibidas en Web of Science: 4
Documentos
- No hay documentos
Filiaciones
Keywords
- anidulafungin; alopecia; hair loss; adverse drug reactions
Campos de Estudio
Cita
RUIZ J,SALAVERT M,MONTE E,LORENTE L,GIL I,POVEDA JL. Anidulafungin-Induced Alopecia. Ann. Pharmacother. 2014. 48. (5):p. 660-662. IF:2,059. (3).
Portal de investigación